TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.48), $0.05 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $30 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.